December 6, 2018
Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit...
Read Press ReleaseDermavant’s
Growing Pipeline
Dermavant is developing investigational drugs to treat atopic dermatitis, acne, hyperhidrosis and other inflammatory skin diseases and medical dermatologic conditions.
Patient-Focused
Innovation
The patient is at the heart of everything we do. It is for them that we harness scientific innovations to provide new treatment options for inflammatory skin diseases and medical dermatologic conditions with unmet medical needs.
December 6, 2018
Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo
Patient-Focused
Innovation
The patient is at the heart of everything we do. It is for them that we harness scientific innovations to provide new treatment options for inflammatory skin diseases and medical dermatologic conditions with unmet medical needs.
